Weight and Healthcare β’ 758 implied HN points β’ 27 May 23
- The study on Wegovy's long-term effects raised concerns about the definition of 'long-term' in the context of a 2-year study.
- The conflicts of interest among the study authors, who receive funding and support from Novo Nordisk, the drug manufacturer, raise questions about the study's credibility.
- The study revealed high rates of adverse events among participants taking Semaglutide, emphasizing the risks associated with such weight loss medications.